肝细胞乙型肝炎核心抗原和乙型肝炎表面抗原作为标记在慢

StephenW

Gut Liver. 2017 Feb 17. doi: 10.5009/gnl16148. [Epub ahead of print]
Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients.Yim SY1, Kim TH1, Jun SS1, Kim ES1, Keum B1, Seo YS1, Yim HJ1, Jeen YT1, Chun HJ1, Lee HS1, Um SH1, Kim CD1, Won NH2, Ryu HS1.
Author information

• 1Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
• 2Department of Pathology, Korea University College of Medicine, Seoul, Korea.
  

AbstractBackground/Aims: We aimed to clarify the association of HBsAg/HBcAg with the disease status and treatment response in patients with chronic hepatitis B (CHB).
Methods: We investigated 171 biopsy-proven entecavir-treated CHB patients (109 HBeAg-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous. The histologic activity index (HAI) and fibrosis stage followed Ishak system.
Results: In HBeAg-positive patients, older age, increased HAI score, advanced fibrosis, and reduced viral load were observed when HBcAg expression shifted from nucleus to cytoplasm in HBcAg-positive patients, and HBsAg expression from non-submembranous to submembranous in HBcAg-negative patients (all, p<0.05). In HBeAg-negative patients, only intracytoplasmic HBsAg expression patterns had clinical relevance with decreased ALT levels and viremia. In HBeAg-positive patients without favorable predictors of virologic response, negative HBcAg and membranous HBsAg expression predicted greater virologic response (both, p<0.05). The probability of HBeAg seroclearance was higher in patients with increased HAI or lacking HBcAg expression (both, p<0.05). Higher serum HBsAg levels and hepatocyte HBcAg positivity were associated with reduced serum HBsAg during first and post-first year treatment, respectively (both, p<0.05).
Conclusions: Hepatocyte HBcAg/HBsAg expression is a good marker for disease status and predicting treatment response.


KEYWORDS: Hepatitis B core antigens; Hepatitis B surface antigens; Hepatitis B, chronic; Histologic activity index

PMID:28208002DOI:10.5009/gnl16148

StephenW

肠肝。 2017年2月17日。doi：10.5009 / gnl16148。 [打印前的电子版]
肝细胞乙型肝炎核心抗原和乙型肝炎表面抗原作为标记在慢性乙型肝炎的管理中的表达。
Yim SY1，Kim TH1，Jun SS1，Kim ES1，Keum B1，Seo YS1，Yim HJ1，Jeen YT1，Chun HJ1，Lee HS1，Um SH1，Kim CD1，Won NH2，Ryu HS1。
作者信息

    韩国大学医学院内科，韩国首尔。
    韩国大学医学院病理学系，韩国首尔。

抽象
背景/目的：

我们旨在澄清HBsAg / HBcAg与慢性乙型肝炎（CHB）患者的疾病状态和治疗反应的关联。
方法：

我们调查171活检证实恩替卡韦治疗CHB患者（109 HBeAg阳性，62 HBeAg阴性）。当≥10％的肝细胞染色时，HBcAg表达是阳性的，并且分类为核，混合和细胞质模式。 HBsAg表达是胞浆内（弥漫性，球状和膜下）和膜状。组织学活性指数（HAI）和纤维化分期遵循Ishak系统。
结果：

在HBeAg阳性患者中，当HBcAg表达从HBcAg阳性患者中的细胞核转移到细胞质时，观察到HBeAg阳性患者的年龄较大，HAI评分增加，晚期纤维化和病毒负荷减少，而HBcAg阴性患者中从非膜下到HBsAg表达HBsAg表达（all，p <0.05）。在HBeAg阴性患者中，只有胞质内HBsAg表达模式具有降低的ALT水平和病毒血症的临床相关性。在没有有利的病毒学应答预测因子的HBeAg阳性患者中，阴性HBcAg和膜性HBsAg表达预测更大的病毒学应答（两者，p <0.05）。 HBeAg血清清除的概率在具有增加的HAI或缺乏HBcAg表达的患者中更高（两者，p <0.05）。较高的血清HBsAg水平和肝细胞HBcAg阳性分别与第一和第一年治疗期间血清HBsAg减少相关（两者，p <0.05）。
结论：

肝细胞HBcAg / HBsAg表达是疾病状态和预测治疗反应的良好标记。
关键词：

乙型肝炎核心抗原;乙型肝炎表面抗原;乙型肝炎，慢性;组织学活性指数

PMID：
    28208002
DOI：
    10.5009 / gnl16148